Merck & Co., Inc. (MRK)

NYSE: MRK · Real-Time Price · USD
83.93
+5.35 (6.81%)
At close: Sep 30, 2025, 4:00 PM EDT
84.47
+0.54 (0.64%)
Pre-market: Oct 1, 2025, 8:45 AM EDT
6.81%
Market Cap209.64B
Revenue (ttm)63.62B
Net Income (ttm)16.41B
Shares Out 2.50B
EPS (ttm)6.49
PE Ratio12.94
Forward PE9.16
Dividend$3.24 (3.86%)
Ex-Dividend DateSep 15, 2025
Volume21,636,633
Open78.42
Previous Close78.58
Day's Range78.40 - 84.00
52-Week Range73.31 - 114.79
Beta0.36
AnalystsBuy
Price Target107.21 (+27.74%)
Earnings DateOct 30, 2025

About MRK

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]

Sector Healthcare
Founded 2000
Employees 75,000
Stock Exchange NYSE
Ticker Symbol MRK
Full Company Profile

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial Statements

Analyst Summary

According to 15 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is $107.21, which is an increase of 27.74% from the latest price.

Price Target
$107.21
(27.74% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Merck to Hold Third-Quarter 2025 Sales and Earnings Conference Call Oct. 30

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Third-Quarter 2025 Sales and Earnings Conference Call Oct. 30.

2 hours ago - Business Wire

S&P 500 Gains and Losses Today: Pfizer and Merck Jump; Payments Stocks Decline

An agreement with the U.S. government and a favorable regulatory decision in Europe helped lift shares of large drugmakers. Meanwhile, the announcement of a collaboration that will integrate shopping ...

Other symbols: PFE
15 hours ago - Investopedia

7 Ideal "Safer" Dividend Buys From 61 September Graham Value All-Stars (GVAS)

The article analyzes Large Cap Value (GASV) stocks using YCharts' Value Score and the Ben Graham Formula to identify fair-priced, high-yield dividend opportunities. Seven of fourteen 'safer' lowest-pr...

Other symbols: BBVABMYCMCSAEEPDETMFC
20 hours ago - Seeking Alpha

Merck: Initiating "Strong Buy" On Shift To Qlex SC Injection For Solid Tumors

Merck earns a "Strong Buy" rating due to strategic moves, including FDA approval of QLEX, the first subcutaneous immune checkpoint inhibitor. QLEX extends Keytruda's patent life, offering rapid, flexi...

22 hours ago - Seeking Alpha

WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase 3 HYPERION trial evaluating WINREVAIR™ (sotatercept...

1 day ago - Business Wire

Pharma tariffs 'not a huge risk' for domestic companies, says Mizuho's Jared Holz

CNBC's “Fast Money” team discusses the potential impact of pharmaceutical tariffs with Jared Holz, healthcare equity strategist at Mizuho.

Other symbols: AZNLLYNVOPFEROG
4 days ago - CNBC Television

Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham

CNBC's “Closing Bell Overtime” team discusses President Trump's plan to impose a 100% tariff on “all any branded or patented Pharmaceutical Product” entering the U.S. with Geoff Meacham of Citi Resear...

Other symbols: ABBVAMGNLLY
4 days ago - CNBC Television

Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen

Courtney Breen, Bernstein senior analyst, joins 'The Exchange' to discuss the companies exempt from pharma tariffs, the country's with existing trade deals and much more.

Other symbols: ABBVAMGNGILDLLYMRNAPFE
4 days ago - CNBC Television

Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access

John Flavin, Portal Innovations founder and CEO, joins CNBC's 'Squawk on the Street' to discuss the Trump administration's proposed pharmaceutical tariffs, the impact on biotech startups and clinical ...

Other symbols: ABBVLLYPFEBIIBBMY
4 days ago - CNBC Television

Merck: Game-Changing Oncology Drugs Power Stock Surge

Despite the challenges Merck's vaccine franchise has faced, demand for its anti-cancer medications remains as high as ever. Welireg sales reached $162 million in Q2 2025, an increase of 18.2% quarter-...

4 days ago - Seeking Alpha

Merck: 25% Total Return CAGR Potential

Merck & Co. is rated a Strong Buy at $79.89, offering robust growth, a 4% yield, and significant undervaluation. MRK's pipeline, led by Keytruda derivatives and new blockbusters from acquisitions like...

5 days ago - Seeking Alpha

Merck's Keytruda gets an upgrade

CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news.

6 days ago - CNBC Television

Merck CEO Rob Davis on FDA approval of Keytruda injection, navigating new vaccine landscape

CNBC's Angelica Peebles and Merck chairman and CEO Rob Davis join 'Squawk Box' to discuss the FDA's approval of the injectable version of Keytruda, pricing for the new injection, navigating the new va...

6 days ago - CNBC Television

Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery

VANCOUVER, British Columbia--(BUSINESS WIRE)-- #AIDD--Variational AI enters Collaboration with Merck to apply Generative AI Drug Discovery platform to design and optimize novel small molecule therapeu...

8 days ago - Business Wire

Merck: Undervalued Pharma Stock With Defensive Approach And Compelling Dividend Yield

Merck trades at 9.09x forward earnings, far below its 23.55x historical multiple and peers, while maintaining strong profitability and a 3.99% dividend yield. Blockbuster drug Keytruda, along with onc...

9 days ago - Seeking Alpha

Undercovered Dozen: Applied Digital, Merck, B2Gold And More

The 'Undercovered' Dozen series highlights 12 lesser-covered stocks weekly, providing investment ideas and sparking community discussion on their potential. Among today's stocks covered are B2Gold, Me...

Other symbols: APLDBTG
10 days ago - Seeking Alpha

FDA Approves Merck's KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYT...

11 days ago - Business Wire

US FDA approves Merck's new injectable version of Keytruda

The U.S. Food and Drug Administration has approved a new formulation of Merck's blockbuster cancer therapy Keytruda that can be administered under the skin, offering a more convenient option of the wi...

11 days ago - Reuters

EMA committee recommends approval for injectable version of Merck's Keytruda

The European Medicines Agency's committee has recommended the approval for a new formulation of Merck's blockbuster cancer therapy Keytruda that can be administered under the skin, the U.S. drugmaker ...

12 days ago - Reuters

Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of RSV in Infants During Their First RSV Season.

12 days ago - Business Wire

Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Produ...

12 days ago - Business Wire

Merck to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 2025

DARMSTADT, Germany--(BUSINESS WIRE)--Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its mul...

14 days ago - Business Wire

Oakmark Funds' Bill Nygren: Here's where to look beyond the Mag 7

Bill Nygren, Oakmark Funds partner and CIO, joins CNBC's 'Closing Bell' to discuss where to find market opportunities outside of tech, why he's keeping an eye on Corebridge Financial and Delta Airline...

Other symbols: CRBGDAL
14 days ago - CNBC Television

Merck: Buy This Dividend Powerhouse While It's Cheap

Merck offers a compelling opportunity for long-term income and value investors, trading near its 52-week low with a 4% dividend yield. MRK's robust drug pipeline, strong balance sheet, and strategic a...

14 days ago - Seeking Alpha

Merck's pneumonia shot shows promise in late-stage study

Drugmaker Merck said on Thursday that its pneumonia shot showed strong immune responses in children and teens who are at higher risk of serious illness, based on results from a late-stage study presen...

20 days ago - Reuters